| Description of Organization and Business Operations | Note 1—Description of Organization and Business Operations Achari Ventures Holdings Corp. I (the “Company”)
was incorporated in Delaware on January 25, 2021. The Company is a blank check company formed for the purpose of entering into a merger,
share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or
more businesses or entities (a “Business Combination”). The Company is not limited to a particular industry
or geographic region for purposes of consummating an initial Business Combination. The Company is an early stage and emerging growth company
and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. As of June 30, 2024, the Company had not commenced
any operations. All activity through June 30, 2024 relates to the Company’s formation, its initial public offering (“Initial
Public Offering”), and, subsequent to the Initial Public Offering, identifying a target company for an initial Business Combination.
The Company will not generate any operating revenues until after the completion of an initial Business Combination, at the earliest. The
registration statement for the Company’s Initial Public Offering was declared effective on October 14, 2021. On October 19, 2021,
the Company consummated the Initial Public Offering of 10,000,000 units (“Units”), each of which consisted of one warrant
and one share of Common Stock (the “Public Shares”) at $10.00 per Unit, generating gross proceeds of $100,000,000, which is
discussed in Note 3. The Company has selected December 31 as its fiscal year end. Simultaneously with the closing of the Initial
Public Offering, the Company consummated the sale of 7,133,333 warrants (“Private Placement Warrants”) at a price of $0.75
per Private Placement Warrant in a private placement to the Company’s sponsor, Achari Sponsor Holdings I LLC (the “Sponsor”),
for gross proceeds of $5,350,000, which is described in Note 4. Offering costs for the Initial Public Offering
amounted to $6,101,730, consisting of $2,000,000 of underwriting fees, $3,500,000 of deferred underwriting fees payable (which are held
in the Trust Account (as defined below)) and $601,730 of other costs. As described in Note 6, the $3,500,000 of deferred underwriting
fee payable is contingent upon the consummation of an initial Business Combination, as further described in the underwriting agreement
entered into in connection with the Initial Public Offering. Following the closing of the Initial Public Offering,
$101,500,000 ($10.15 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the Private Placement
Warrants was placed in a trust account (the “Trust Account”) and invested in U.S. government securities, within the meaning
set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity
of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting
the conditions of paragraphs (d)(2), (d)(3) and (d)(4) of Rule 2a-7 of the Investment Company Act, as determined by the Company, until
the earlier of: (i) the completion of an initial Business Combination and (ii) the distribution of the Trust Account, as described below. The Company’s management has broad discretion
with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants,
although substantially all of the net proceeds are intended to be applied generally toward consummating an initial Business Combination.
There is no assurance that the Company will be able to complete an initial Business Combination successfully. The Company must complete
one or more Business Combinations having an aggregate fair market value of at least 80% of the assets held in the Trust Account (excluding
the deferred underwriting commissions and taxes payable on income earned on the Trust Account) at the time of the agreement to enter into
the initial Business Combination. However, the Company will only complete an initial Business Combination if the post-transaction company
owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target
sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance the
Company will be able to successfully effect an initial Business Combination. The Company will provide the holders of the outstanding
Public Shares (the “Public Stockholders”) with the opportunity to redeem all or a portion of their Public Shares upon the
completion of an initial Business Combination either (i) in connection with a stockholder meeting called to approve the initial Business
Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of an initial Business
Combination or conduct a tender offer will be made by the Company. The Public Stockholders will be entitled to redeem their Public Shares
for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.15 per Public Share, plus any pro rata
interest then in the Trust Account, net of taxes payable). There will be no redemption rights with respect to the Company’s warrants. All of the Public Shares contain a redemption
feature which allows for the redemption of the Public Shares in connection with the Company’s liquidation, if there is a stockholder
vote or tender offer in connection with the Company’s initial Business Combination and in connection with certain amendments to
the Company’s Sixth Amended and Restated Certificate of Incorporation (as defined below). In accordance with ASC 480-10-S99, redemption
provisions not solely within the control of a company require Common Stock subject to redemption to be classified outside of permanent
equity. Given that the Public Shares were issued with other freestanding instruments (i.e., Public Warrants (as defined in Note 3)), the
initial carrying value of Common Stock classified as temporary equity was the allocated proceeds determined in accordance with Accounting
Standards Codification (“ASC”) 470-20. The Common Stock is subject to ASC 480-10-S99. If it is probable that the equity instrument
will become redeemable, the Company has the option to either (i) accrete changes in the redemption value over the period from the date
of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption
date of the instrument or (ii) recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the
instrument to equal the redemption value at the end of each reporting period. The Company elected to recognize the changes immediately. Redemptions of the Company’s Public Shares
may be subject to the satisfaction of conditions, including minimum cash conditions, pursuant to an agreement relating to the Company’s
initial Business Combination. If the Company seeks stockholder approval of the initial Business Combination, the Company will proceed
with an initial Business Combination if a majority of the shares voted are voted in favor of the initial Business Combination, or such
other vote as required by law or stock exchange rule. If a stockholder vote is not required by applicable law or stock exchange listing
requirements and the Company does not decide to hold a stockholder vote for business or other reasons, the Company will, pursuant to its
Sixth Amended and Restated Certificate of Incorporation, conduct the redemptions pursuant to the tender offer rules of the United States
Securities and Exchange Commission (the “SEC”) and file tender offer documents with the SEC prior to completing an initial
Business Combination. If, however, stockholder approval of the transaction is required by applicable law or stock exchange listing requirements,
or the Company decides to obtain stockholder approval for business or other reasons, the Company will offer to redeem shares in conjunction
with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval
in connection with an initial Business Combination, the Sponsor has agreed to vote its Founder Shares (as defined in Note 5) and any Public
Shares purchased during or after the Initial Public Offering in favor of approving an initial Business Combination. Additionally, each
Public Stockholder may elect to redeem their Public Shares without voting, and if they do vote, irrespective of whether they vote for
or against the proposed transaction. Notwithstanding the foregoing, the Sixth Amended
and Restated Certificate of Incorporation provides that a Public Stockholder, together with any affiliate of such stockholder or any other
person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate
of 15% or more of the Common Stock sold in the Initial Public Offering, without the prior consent of the Company. The Company’s Sponsor, officers and directors
(the “Initial Stockholders”) agreed not to propose an amendment to the Sixth Amended and Restated Certificate of Incorporation
that would affect the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not
complete an initial Business Combination, unless the Company provides the Public Stockholders with the opportunity to redeem their shares
of Common Stock in conjunction with any such amendment. If the Company is unable to complete an initial
Business Combination by October 19, 2024 (assuming each of the July 2024 Monthly Extension Options (as defined below) are exercised, the
“Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as
reasonably possible but not more than 10 business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal
to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not
previously released to us to pay taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding
Public Shares, which redemption will completely extinguish Public Stockholders’ rights as stockholders (including the right to receive
further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption,
subject to the approval of our remaining stockholders and our board of directors, dissolve and liquidate, subject in each case to obligations
under Delaware law to provide for claims of creditors and the requirements of other applicable law. In such case, Public Stockholders
may only receive $10.15 per share (the amount originally deposited in the Trust Account upon the consummation of the Initial Public Offering),
and the warrants will expire worthless. In certain circumstances, Public Stockholders may receive less than $10.15 per share (the amount
originally deposited in Trust Account upon the consummation of the Initial Public Offering) on the redemption of their Public Shares. On July 16, 2024, the Company held a special meeting
of the Company’s shareholders (the “July 2024 Special Meeting”). At the July 2024 Special Meeting, the Company’s
shareholders approved (i) a proposal to amend our Fifth Amended and Restated Certificate of Incorporation (as defined below) to revise
our then-existing extension option, which provided that the Company had the option of extending the period by which we must consummate
a business combination by up to 18 months, from our Original Expiration Date of January 19, 2023 to the Third Amended Extended Date of
July 19, 2024, to instead provide that we have the option to extend the period by which we must consummate a business combination by an
additional three months, from the Third Amended Extended Date, or from July 19, 2024, to October 19, 2024 (the “Fourth Amended Extended
Date”), with such extension option exercisable in three single-month increments (each such monthly extension option, a “July
2024 Monthly Extension Option”), for an additional three-month aggregate total extension period if each July 2024 Monthly Extension
Option is exercised, and with each such July 2024 Monthly Extension Option exercisable upon five calendar days’ advance notice prior
to the applicable monthly deadline (such deadline for exercising each such July 2024 Monthly Extension Option being the 19th calendar
day of each month and, for the avoidance of doubt, the first July 2024 Monthly Extension Option under the Sixth Amended and Restated Certificate
of Incorporation being exercisable at any time on or prior to July 19, 2024), and (ii) a proposal to amend our Third Amended and Restated
Investment Management Trust Agreement, dated December 19, 2023, by and between the Trustee and the Company (the “Third Amended and
Restated Trust Agreement”), to provide that the Third Amended Extended Date of July 19, 2024 provided for in the Third Amended and
Restated Trust Agreement, upon which assets held in the Trust Account will be liquidated if we have not consummated a business combination,
may be extended, at our option, and on a monthly basis, pursuant to the exercise of July 2024 Monthly Extension Option(s), up to and until
the Fourth Amended Extended Date of October 19, 2024; provided that, in order to exercise a single July 2024 Monthly Extension Option,
we must deposit into the Trust Account the lesser of (x) $100,000 and (y) $0.04 for each share of our Common Stock included in the units
which were sold in our Initial Public Offering and which remain outstanding on the date of such deposit. The Company entered into the
Fourth Amended and Restated Trust Agreement on July 16, 2024 with the Trustee. The Sixth Amended and Restated Certificate of Incorporation
was filed with the Delaware Secretary of State on July 16, 2024. The Initial Stockholders agreed to waive their
liquidation rights with respect to the Founder Shares if the Company fails to complete an initial Business Combination within the Combination
Period in connection with the consummation of the Initial Public Offering. However, if the Initial Stockholders decide to acquire Public
Shares in addition to their Founder Shares, they will be entitled to liquidating distributions from the Trust Account with respect to
such Public Shares if the Company fails to complete an initial Business Combination within the Combination Period. The underwriters agreed
to waive their rights to its deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not
complete an initial Business Combination within the Combination Period and, in such event, such amounts will be included with the other
funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution,
it is possible that the per share value of the residual assets remaining available for distribution (including the Trust Account assets)
will be only $10.15 per shares held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed
to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective
target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account.
This liability will not apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim
of any kind in or to any monies held in the Trust Account or to any claims under the Company’s indemnity of the underwriters of
the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities
Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not
be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor
will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except the
Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company
does business, execute agreements waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. Business Combination Agreement with Vaso
Corporation Business Combination Agreement The Company entered into a business combination
agreement (the “Vaso Business Combination Agreement”), dated as of December 6, 2023, with Vaso Corporation, a Delaware corporation
(“Vaso”), and Achari Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Achari (“Merger Sub”).
The Vaso Business Combination Agreement provides, among other things, that on the terms and subject to the conditions set forth therein,
Merger Sub will merge with and into Vaso (the “Merger”), with Vaso surviving as a wholly-owned subsidiary of the Company (the
“Surviving Company”). Upon the closing of the Vaso Business Combination Agreement (the “Closing”), it is anticipated
that the Company will change its name to “Vaso Holding Corporation” (or an alternative name chosen by Vaso and reasonably
acceptable to the Company). The Merger and the other transactions contemplated
by the Vaso Business Combination Agreement are hereinafter referred to collectively as the “Vaso Business Combination.” The Vaso Business Combination Agreement and the
transactions contemplated thereby were approved by the boards of directors of each of the Company, Vaso and Merger Sub. In connection with the Vaso Business Combination,
the Company filed a registration statement on Form S-4 with the Securities and Exchange Commission (the “SEC”) on January
8, 2024 (Registration No. 333-276422) (the “Registration Statement”). On February 2, 2024, the Company received a comment
letter from the SEC regarding the Registration Statement. The Company responded to the SEC’s comment letter and amended the Registration
Statement on February 14, 2024, accordingly. On March 8, 2024, the Company received a second comment letter from the SEC regarding the
Registration Statement. The Company responded to the SEC’s comment letter and amended the Registration Statement on April 9, 2024,
accordingly. On April 22, 2024, the Company received a third comment letter from the SEC regarding the Registration Statement. The Company
responded to the SEC’s comment letter and amended the Registration Statement on April 30, 2024, accordingly. On May 9, 2024, the
Company received a fourth comment letter from the SEC regarding the Registration Statement. The Company responded to the SEC’s comment
letter and amended the Registration Statement on May 28, 2024, accordingly. On June 10, 2024, the Company received a fifth comment letter
from the SEC regarding the Registration Statement. The Company responded to the SEC’s comment letter and amended the Registration
Statement on June 14, 2024, accordingly. On June 24, 2024, the Company received a sixth comment letter from the SEC regarding the Registration
Statement. The Company responded to the SEC’s comment letter and amended the Registration Statement on July 5, 2024, accordingly.
The Company filed a further amended Registration Statement on each of (i) July 18, 2024, which Registration Statement was deemed filed
on July 19, 2024; (ii) July 25, 2024; and (iii) August 1, 2024, accordingly. On August 5, 2024, the Registration Statement was declared
effective. On August 7, 2024, the Company filed a definitive joint proxy statement/prospectus (the “Definitive Proxy Statement”)
with respect to an extraordinary general meeting (the “Extraordinary General Meeting”) of the Company’s stockholders
which is being convened so that the Company’s stockholders may vote upon certain proposals, including with respect to approval of
the previously announced transactions contemplated by the Vaso Business Combination Agreement. The Extraordinary General Meeting shall
be held virtually at 1:00 p.m. Eastern Time on August 26, 2024 at https://www.cstproxy.com/acharivc/bc2024 and the record date for determining
those stockholders who shall be entitled to vote at the Extraordinary General Meeting was August 8, 2024. For additional information regarding
the Vaso Business Combination and the Extraordinary General Meeting, please see the Registration Statement, as amended, and the Definitive
Proxy Statement, respectively. Consideration and Structure In accordance with the terms and subject to the
conditions of the Vaso Business Combination Agreement, at the effective time of the Merger (the “Effective Time”), (i) each
share of capital stock of Merger Sub issued and outstanding immediately prior to the Effective Time shall be automatically cancelled and
extinguished and converted into one share of common stock, par value $0.01 per share, of the Surviving Company; and (ii) each share of
common stock, par value $0.001 per share, of Vaso (each, a “Vaso Share”) (excluding any dissenting shares and any Vaso Shares
held immediately prior to the Effective Time by Vaso as treasury stock) issued and outstanding as of immediately prior to the Effective
Time shall be automatically cancelled and extinguished and converted into the right to receive a number of shares of the Company’s
Common Stock, par value $0.0001 per share, in accordance with an exchange ratio equal to (i) the quotient of (a) $176,000,000, divided
by (b) the fully-diluted shares of Vaso common stock outstanding on the date of the calculation, divided by (ii) $10.00. The Vaso Business
Combination is expected to close in the third quarter of 2024, following the receipt of the required approval by the stockholders of the
Company and Vaso. Representations and Warranties; Covenants The parties to the Vaso Business Combination Agreement
have agreed to customary representations and warranties for transactions of this type. In addition, the parties to the Vaso Business Combination
Agreement agreed to be bound by certain customary covenants for transactions of this type, including, among others, covenants with respect
to the conduct of the Company, Vaso and their respective subsidiaries during the period between execution of the Vaso Business Combination
Agreement and Closing. The representations, warranties, agreements and covenants of the parties set forth in the Vaso Business Combination
Agreement will terminate at Closing, except for those covenants and agreements that, by their respective terms, contemplate performance
after Closing. Each of the parties to the Vaso Business Combination Agreement has agreed to use its reasonable best efforts to take or
cause to be taken all actions and things necessary to consummate the Vaso Business Combination. Conditions to Closing The obligations of the Company and Vaso to consummate
the Vaso Business Combination are subject to the fulfillment or waiver of certain closing conditions, including, but not limited to: (i)
no order or law issued by any court of competent jurisdiction or other governmental entity or other legal restraint or prohibition preventing
the consummation of the transactions contemplated by the Vaso Business Combination Agreement being in effect; (ii) the approval and adoption
of the Vaso Business Combination Agreement and the transactions contemplated thereby by the requisite vote of the Company’s and
Vaso’s stockholders; (iii) the registration statement/proxy statement to be filed by the Company relating to the Vaso Business Combination
Agreement and the Vaso Business Combination becoming effective in accordance with the provisions of the Securities Act, no stop order
being issued by the SEC and remaining in effect with respect to the registration statement/proxy statement to be filed by the Company
relating to the Vaso Business Combination Agreement and the Vaso Business Combination, and no proceeding seeking such a stop order being
threatened or initiated by the SEC and remaining pending; (iv) the Certificate of Merger having been accepted for filing by the Secretary
of State of the State of Delaware; and (v) the absence of the occurrence of a material adverse effect on the part of the Company and/or
Vaso. Termination The Vaso Business Combination Agreement may be
terminated under customary and limited circumstances prior to the Closing, including, but not limited to: (i) by mutual consent of the
Company and Vaso; (ii) by either the Company or Vaso if there is a law or governmental order in effect prohibiting the Vaso Business Combination;
provided that this right shall not be available to the party whose breach of any of its representations, warranties, covenants or agreements
under the Vaso Business Combination Agreement results in or is the primary cause of such law or governmental order; and (iii) by either
the Company or Vaso if the Merger is not consummated on or before May 30, 2024, which date shall be extended automatically for up to thirty
(30) days to the extent the parties to the Vaso Business Combination Agreement are continuing to work in good faith toward the Closing. The foregoing description of the Vaso Business
Combination Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the Vaso Business
Combination Agreement, a form of which is attached as Exhibit 2.1 to the Company’s Annual Report on Form 10-K filed with the Securities
and Exchange Commission on March 29, 2024, and the terms of which are incorporated herein by reference. The Vaso Business Combination Agreement contains
representations, warranties and covenants that the respective parties thereto made to each other as of the date of such agreement or other
specific dates. The assertions embodied in those representations, warranties and covenants were made for purposes of the agreement among
such parties and are subject to important qualifications and limitations agreed to by such parties in connection with negotiating such
agreement. The representations, warranties and covenants in the Vaso Business Combination Agreement are also modified in important part
by the underlying disclosure schedules, which are not filed publicly, and which are subject to a contractual standard of materiality different
from that generally applicable to stockholders, and which were used for the purpose of allocating risk among the parties rather than establishing
matters as facts. The Company and Vaso believe that these disclosure schedules do not contain information that is material to an investment
or voting decision. Other Agreements Sponsor Letter Agreement The Vaso Business Combination Agreement contemplates
that, at or prior to the Closing, the Sponsor, will enter into a Sponsor Letter Agreement with the Company, Vaso and the other parties
thereto (the “BCA Sponsor Letter Agreement”), which (among other things) outlines the transfer of Founder Shares and Private
Placement Warrants by the Sponsor to the Company, and also provides for guidelines of restrictions and agreements regarding voting, redemption
and disposition of these securities. Pursuant to the BCA Sponsor Letter Agreement, the Sponsor is to return 1,750,000 Founder Shares and
6,133,000 Private Placement Warrants to the Company at the time of the initial Business Combination. The agreement also includes representations
and warranties by the parties involved and conditions for termination in compliance with the Vaso Business Combination Agreement. The foregoing description of the BCA Sponsor Letter
Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the BCA Sponsor Letter Agreement,
a form of which is attached as Exhibit 10.1 to the Annual Report, and the terms of which are incorporated herein by reference. Put Option Agreement The Vaso Business Combination Agreement contemplates
that, simultaneously with the Closing, the Sponsor, the Company and Vaso will enter into a Put Option Agreement (the “Put Option
Agreement”), which (among other things) governs the transfer and exercise of put options for certain shares and provides a framework
for the transfer and exercise of these put options, outlining specific conditions and procedures for their exercise. The Sponsor will
then gain the right to put up to 750,000 Class A Common Stock, par value $0.0001 per share, of the post-Vaso Business Combination company
at $8.00 per share (the “Achari Put Options”). If the Closing occurs, then Vaso shall pay, or cause to be paid up to $4,500,000
of all Unpaid SPAC Expenses (as defined in the Vaso Business Combination Agreement). If Vaso pays, or causes to be paid, more than $2,250,000
of Unpaid SPAC Expenses, then (i) the number of shares subject to the Achari Put Options shall be reduced by a number of shares equal
to the quotient of the excess amount divided by $8.00 and (ii) the number of shares that the holder of such Achari Put Options is to maintain
as a result of the BCA Sponsor Letter Agreement shall be reduced from 750,000 by a number of shares equal to the quotient of the Additional
Unpaid SPAC Expenses Amount (as defined in the Put Option Agreement) divided by $8.00. The form of Put Option Agreement was subsequently
amended to provide that Vaso may terminate the Business Combination Agreement if Unpaid SPAC Expenses exceed $4,500,000; provided, however,
if the Business Combination Agreement is not terminated, then (i) the number of shares subject to the Achari Put Options shall be reduced
by a number of shares equal to the quotient of the excess amount over $4,500,000 divided by $5.00, and (ii) the number of shares that
the holder of such options is required to maintain as a result of the Sponsor Letter Agreement shall be further reduced by a number of
shares equal to the quotient of the excess amount over $4,500,000 divided by $5.00. The holders of such Achari Put Options may exercise
them in certain periods: the initial put exercise period, which shall begin 12 months after the consummation of the initial Business Combination
and end three months thereafter, and the second put exercise period, which shall begin three months after the start of the initial put
exercise period and end three months thereafter. During these periods, they can sell up to 50% of the Achari Put Option shares to the
Company, with unexercised options expiring at the end of each period. The Sponsor retains sole responsibility for any cash proceeds resulting
from exercising these Achari Put Options. If market conditions permit, (i) the holders of the Achari Put Option shares may sell these
shares prior to the expiration of the lock-up period described in the Put Option Agreement, and (ii) the post-Vaso Business Combination
company may require the mandatory sale to the post-Vaso Business Combination company of Achari Put Option shares. The foregoing description of the Put Option Agreement
does not purport to be complete and is qualified in its entirety by the terms and conditions of the Put Option Agreement, a form of which
is attached as Exhibit 10.2 to the Annual Report, and the terms of which are incorporated herein by reference. Amended and Restated Registration Rights Agreement The Vaso Business Combination Agreement contemplates
that, simultaneously with the Closing, the Company and certain security holders and/or executive officers and directors of the Company
and Vaso will enter into an Amended and Restated Registration Rights Agreement (the “Amended and Restated Registration Rights Agreement”),
which serves to register certain shares, such as Founder Shares and common shares underlying the Private Placement Warrants, for resale
under the Securities Act. Such agreement details provisions for shelf registrations, including the filing of Registration Statements (Form
S-1 Shelf or Form S-3 Shelf), maintaining shelf effectiveness, amendments and subsequent registrations for resale of registrable securities.
Additionally, such agreements outline the Company’s obligations to facilitate the disposition of registra |
